A recent study [24] demonstrated that patients taking anti-TNF-α drugs to improve immune-mediated inflammatory disease (IMID) conditions did not show compromised health after contracting COVID-19; on the contrary, they fared better than their counterparts. This evidence concerns the gene TNF and COVID-19.